08.08.2011 • NewsArch ChemicalsQ2 2011sales and profits

Arch Chemicals Q2 Profit Falls

Biocides company Arch Chemicals, which is in $1.4 billion cash deal to be acquired by Lonza reported that its second-quarter earnings from continuing operations was $37.4 million or $1.47 per share, lower than prior year's $43.5 million or $1.73 per share.

The latest quarter results included a charge of $0.3 million or $0.01 per share, for relocation costs incurred in conjunction with the previously announced research and development consolidation.

Excluding this item, earnings from continuing operations for 2011 were $37.7 million or $1.48 per share.

Analysts polled by Thomson Reuters expected earnings of $1.82 per share for the quarter. Analysts' estimates typically exclude special items.
The company noted that the second-quarter earnings were significantly impacted by lower-than-expected results from the HTH water products business, principally due to timing.

Sales for the second quarter were $443.8 million, compared to $441.4 million for the second quarter of 2010.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read